Bipartisan Insulin Cost Cap Bill: What It Means for Millions With Diabetes

Why Is Insulin So Expensive in the United States?

The United States has long been an outlier in insulin pricing. While insulin was discovered over a century ago and costs only a few dollars per vial to manufacture, list prices in the U.S. have historically reached hundreds of dollars per vial. According to the RAND Corporation, Americans pay roughly two to three times more for insulin than people in other high-income nations. This disparity is driven by a complicated supply chain involving pharmaceutical manufacturers, pharmacy benefit managers (PBMs), and health insurers, each adding layers of cost.

For the estimated 8.4 million Americans who depend on insulin daily, these prices can be devastating. Studies published in journals including JAMA Internal Medicine have documented that roughly one in four insulin users report rationing their doses due to cost — skipping injections, using less than prescribed, or delaying refills. Insulin rationing has been linked to diabetic ketoacidosis, hospitalizations, and preventable deaths, making affordability a genuine life-or-death issue.

What Would the New Bipartisan Bill Actually Do?

The new bipartisan bill builds on the insulin cost cap that was included in the Inflation Reduction Act of 2022, which limited out-of-pocket insulin costs to $35 per month — but only for Medicare beneficiaries. The proposed legislation aims to extend this $35 monthly cap to all Americans, including those with private insurance and the uninsured. Diabetes advocacy organizations, including the American Diabetes Association and JDRF, have voiced strong support for the measure.

Supporters argue that insulin is not a luxury but a basic necessity for survival, particularly for the approximately 1.9 million Americans with type 1 diabetes who produce no insulin naturally. The bill also addresses insulin pump supplies and related diabetes management costs. Critics have raised questions about how the cap would be enforced for uninsured patients and whether manufacturers might shift costs elsewhere. However, major insulin manufacturers — including Eli Lilly, Novo Nordisk, and Sanofi — have already voluntarily reduced list prices in recent years, suggesting the industry may be moving toward broader affordability even without legislation.

How Does Insulin Affordability Affect Health Outcomes?

The link between insulin affordability and health outcomes is well established. The CDC reports that diabetes is the eighth leading cause of death in the United States and a major contributor to heart disease, kidney failure, blindness, and lower-limb amputations. When patients cannot afford consistent insulin therapy, blood glucose levels become erratic, accelerating the development of these complications. Emergency department visits for diabetic crises cost the healthcare system billions of dollars annually — far exceeding the cost of affordable insulin access.

Research from the Yale Diabetes Center and other institutions has shown that even modest reductions in out-of-pocket costs significantly improve medication adherence. Following the 2022 Medicare cap, early data indicated improved refill rates among Medicare beneficiaries. Expanding this cap to the broader population could yield similar benefits, potentially reducing hospitalizations and long-term complications. Public health experts emphasize that insulin pricing is not merely an economic issue but a health equity concern, as cost-related rationing disproportionately affects Black, Hispanic, and low-income communities who already bear a higher burden of diabetes.